Gene therapy preparations manufacturing · Massachusetts

Brammer Bio Lexington

Lexington, MA · ~151 workers · 7 years of OSHA Injury Tracking Application data.

A
Excellent Safety Record
0.3
Avg TCR
3.3
Industry avg
0
Fatalities
Subscribe to safety-record updates (RSS)

The verdict

Brammer Bio Lexington runs at 10% of its industry's injury rate - far safer than the typical Gene therapy preparations manufacturing workplace, earning a grade A.

Brammer Bio Lexington: 0.3 TCR = 10% of Gene therapy preparations manufacturing BLS 3.3 · 7y Form 300A (see methodology below)

Brammer Bio Lexington safety composite

Brammer Bio Lexington scores strongest on total case rate (tcr) (safer than 89% of same-industry peers) and weakest on fatalities (safer than 50%), blended into one 0-100 breakdown against same-industry peers. A missing measure drops out and redistributes its weight rather than deflating the score. This is a per-dimension breakdown, distinct from the single letter grade above it (which weights TCR alone against the BLS industry benchmark).

B

77/100

Percentile-weighted across 3 of 3 measures

Total Case Rate (TCR)
B 0.33 per 100 workers

Safer than 89% of industry peers

DART rate
B 0 per 100 workers

Safer than 83% of industry peers

Fatalities
D 0

Safer than 50% of industry peers

Benchmarked live against every credibly-rated employer in the same NAICS industry code in the current OSHA extract (a segment must have at least 8 rated peers to benchmark). Not a legal or compliance determination; PlainSafetyScore's own weighting (TCR 40%, DART 35%, fatalities 25%).

Brammer Bio Lexington held a steady TCR band

Brammer Bio Lexington's TCR held near 0.0 from 0.0 in 2018 to 0.0 in 2024. Peak filing year was 2020 at 1.4 TCR. In 2024, DART was 0× this establishment's average TCR (severity share of cases).

2018=0.0 · 2019=0.0 · 2020=1.4 · 2021=0.9 · 2022=0.0 · 2023=0.0 · 2024=0.0

OSHA ITA Form 300A scorecard

Establishment book 325414 · Lexington, MA AT/BELOW-IND · MID

Grade A · TCR 0.3 · 10% of ind

  • DART 0.0 DART
  • RANK #8/37
  • PHOTO Recursion Pharmaceut…
  • BOOK 7y book
  • INJ 3 inj
  • SIZE ~151 FTE

Nearest TCR peer: Recursion Pharmaceuticals HQ (0.0 TCR gap)

Read with this employer → · Industry book → · Massachusetts employers → · Look up another →

Brammer Bio Lexington in the TCR neighbourhood

Average Total Case Rate among this establishment and nearest same-industry peers

TCR

What this shows Brammer Bio Lexington averages 0.3 TCR (10% of the Gene therapy preparations manufacturing BLS benchmark).

Source U.S. Department of Labor, OSHA Injury Tracking Application (Form 300A) As of 2026-08-25

Brammer Bio Lexington TCR series: 2018=0 · 2019=0 · 2020=1.4 · 2021=0.9 · 2022=0 · 2023=0 · 2024=0 · BLS 3.3

Where Brammer Bio Lexington falls in its industry

234 Gene therapy preparations manu establishments

Safer than 89% of graded establishments in this industry, whose median TCR is 1.2.

More dangerous than peersSafer than peers

Narrower to Massachusetts alone (the establishments it most directly competes with for workers and contracts): ranked #8 safest of 37 Gene therapy preparations manu employers in Massachusetts.

Brammer Bio Lexington (151 employees, TCR 0.3) among 29 same-industry peers, split at the industry median of 198 employees and a TCR of 1.2 2×2 strategic matrix plotting 30 entities by Average employees (X) and Total Case Rate (Y), with a crosshair dividing the plot into four quadrants. Larger & higher-riskSmaller & higher-riskLarger & saferSmaller & safer than peers 05001,0001,5002,000 0246 Average employees Total Case Rate Brammer Bio Lexington
Brammer Bio Lexington (151 employees, TCR 0.3) among 29 same-industry peers, split at the industry median of 198 employees and a TCR of 1.2

Brammer Bio Lexington has fewer employees than the Gene therapy preparations manufacturing median and a lower injury rate than the industry's median TCR of 1.2. Workforce size and injury rate do not always move together within the same industry -- some of its smaller peers run higher rates than its larger ones, and vice versa.

Year-by-Year Safety Data

Year TCR DART Injuries Illnesses Fatalities
2024 0.0 0.0 0 0 0
2023 0.0 0.0 0 0 0
2022 0.0 0.0 0 0 0
2021 0.9 0.5 1 1 0
2020 1.4 1.4 2 0 0
2019 0.0 0.0 0 0 0
2018 0.0 0.0 0 0 0

OSHA ITA peer cross-reference

Establishment peer ledger

325414 · MA · Lexington

234 Gene therapy preparations manufacturing employers nationwide with a credible TCR · 10,108 rated employers in Massachusetts with headcount on file · 48 employers in Lexington, MA · 4 cross-state NAT-TCR peers · 4 cross-state NAT-SIZE peers. Closest matches by relationship code are listed below.

Rel Establishment Metric
NAICS-TCR Recursion Pharmaceuticals HQ 0.3 TCR
NAICS-TCR Sanofi Pastuer Field Sales North Central Region 0.3 TCR
NAICS-TCR Andelyn Biosciences - Corporate Center 0.3 TCR
NAICS-TCR Boehringer Ingelheim Duluth 0.3 TCR
STATE-SIZE HOPEDALE-MA14 151 FTE
STATE-SIZE NER 151 FTE
STATE-SIZE Hazen Paper - Main Plant 151 FTE
STATE-SIZE Anika Therapeutics - Bedford 151 FTE
CITY-NEAR Takeda: USA Field Sales Employees 2,980 FTE
CITY-NEAR KabaFusion Holdings LLC 1,755 FTE
CITY-NEAR Shire: USA Field/Sales Employees 1,615 FTE
CITY-NEAR Fujifilm Healthcare Americas Corporation Lexington 960 FTE
NAT-TCR Aim Integrated Corporate 0.3 TCR
NAT-TCR New Indy-Catawba 0.3 TCR
NAT-TCR Old Perkins Facility 0.3 TCR
NAT-TCR Dish Tech - 90 Inverness 0.3 TCR
NAT-SIZE Public Works Agency 151 FTE
NAT-SIZE Delta Farm Packing 151 FTE
NAT-SIZE Ocean Beach Hospital 151 FTE
NAT-SIZE The Woodlands Nursing and Rehabilitation Center 151 FTE

Rel codes: NAICS-TCR · STATE-SIZE · CITY-NEAR · NAT-TCR/NAT-SIZE cross-state. Read with this employer →

Data Source: OSHA Injury Tracking Application (ITA), mandatory establishment-level injury/illness reports. Grades compare employer Total Case Rate (TCR) to BLS IIF industry benchmarks. Data covers years reported by this establishment: 2024, 2023, 2022, 2021, 2020, 2019, 2018. This is publicly available government data - not a legal determination of workplace conditions.
Data sourced from official public datasets. See our methodology for details.